(Medical Xpress)—A team of researchers with member affiliations to institutions in the U.S. and Germany has uncovered the mechanism by which a cancer fighting drug reduces cancer cells and also helps patients with a blood ...
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.
Dec 15, 2018
0
58
Research on the same protein that was a primary mediator of the birth defects caused by thalidomide now holds hope in the battle against multiple myeloma, says the study's senior investigator, Keith Stewart, M.B., Ch.B. of ...
Dec 11, 2011
0
0
A case study published in the August issue of the journal CHEST found lenalidomide treatments may have an immediate effect in the treatment of sarcoidosis-related symptoms. Sarcoidosis, a disease that involves abnormal collections ...
Aug 4, 2015
0
6
A drug has been made available on the NHS in England for adults with a type of blood cancer called multiple myeloma who cannot receive standard treatment.
May 20, 2019
0
1
An early benefit assessment conducted by the German Institute for Quality and Efficiency in Health Care (IQWiG) in 2020 already addressed the question of whether daratumumab in combination with lenalidomide and dexamethasone ...
Jan 4, 2022
0
14
(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according ...
May 2, 2012
0
0
An early phase multiple myeloma trial has unexpectedly revealed that the drug lenalidomide interacts with another protein in cells that affect its dose level in the body, say researchers at the Ohio State University Comprehensive ...
Aug 8, 2011
0
0
(HealthDay)—Rituximab plus lenalidomide has similar efficacy to rituximab plus chemotherapy among patients with previously untreated follicular lymphoma, according to a study published in the Sept. 6 issue of the New England ...
Sep 12, 2018
0
0
(Medical Xpress) -- A three-drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej ...
Dec 8, 2011
0
0
Lenalidomide ( /lɛnəˈlɪdɵmaɪd/), initially known as CC-5013 and marketed as Revlimid by Celgene, is a derivative of thalidomide introduced in 2004.
It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS). Lenalidomide and bortezomib are considered therapeutic breakthroughs in the treatment of myeloma, which generally carries a poor prognosis.
This text uses material from Wikipedia, licensed under CC BY-SA
